Parkinson’s disease

β2-Adrenergic Agonists for Parkinson’s Disease: Repurposing Drugs at the Crossroad of the Brain and the Immune System

β2-Adrenergic Agonists for Parkinson’s Disease: Repurposing Drugs at the Crossroad of the Brain and the Immune System

Commentary On the study by Mittal S, Science, 2017; 357(6354):891-898. doi: 10.1126/science.aaf3934 β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease Parkinson’s disease (PD) affects 0.1-0.2% of the general population with increasing prevalence with age, and up to 1% in individuals above 60 years of age, resulting in an estimated 7 […]

Massachusetts Neuroscience Consortium: A Collaborative Model between Government, Academia and Industry

Massachusetts Neuroscience Consortium: A Collaborative Model between Government, Academia and Industry

Laboratories in academia and industry often work independently, but recently, a coalition of academic researchers, pharmaceutical companies and state governments announced the formation of the Massachusetts Neuroscience Consortium. The $1.75 million partnership intends to fundamentally shift the neurological disease research. Founders of this new project recognized that a highly collaborative and coordinated effort must be […]